News

Newest drug developments for haemophilia seek to combine a highly potent bleed protection with the lowest possible treatment burden to permit patients an almost normal life.

With the introduction of gene therapy, this goal is getting closer, although there are still some hurdles to take.

The Charité Research Organisation GmbH has profound experience in the conduction of early phase projects for new medicines to treat haemophilia A.

We want to share our expertise in this Whitepaper.

Author and Contact:
Claudia Werner, MD, PhD
Charité Research Organisation GmbH
Charitéplatz 1, 10117 Berlin
claudia.werner@charite-research.org